For 40 years, HIV vaccine researchers have chased a particular kind of antibody: one that could recognize the virus no matter how much it mutates. Three new studies in Nature, described in a companion analysis co-written by WaNBRC’s Dr. Cynthia Derdeyn, show that scientists can now reliably coax the immune system toward making one.
The antibodies are called “broadly neutralizing antibodies,” or bnAbs. HIV survives by constantly reshuffling its surface protein, called Env, and wrapping it in a shifting cloak of molecules. Most antibodies get fooled. But in a small number of people living with HIV, years of exposure to the evolving virus eventually produce antibodies that see past the disguise and neutralize many different strains at once. If a vaccine could trigger that same response faster, it could offer real protection against infection.
That’s what the three studies set out to test in rhesus macaques, whose B-cell biology is unusually close to humans’. All three used a “prime-then-boost” strategy: an engineered first dose designed to grab the attention of rare, bnAb-prone B cells, followed by a series of booster shots that gradually introduce more of the changes the virus shows during a real infection. The idea is to recreate, on a compressed timeline, the slow co-evolution between virus and immune system that produces bnAbs naturally.
The approaches differed in the details, but the results were clear: Many of the animals in all three studies developed circulating antibodies that could neutralize a diverse panel of HIV strains. That means the vaccines aren’t just producing some protective antibody, they’re producing the kind the human immune system is already known to make under the right, rare, conditions.
To be clear about the limits, none of the studies tested whether the antibody responses actually prevent infection, and nobody yet knows how long the protection would last. More research is needed.
Still, this is real forward motion on one of vaccinology’s hardest problems. Components from two of the three strategies are already in early human clinical trials. The next tests will determine whether this preclinical proof of concept becomes something people can actually get a shot of.
The studies:
- https://www.nature.com/articles/s41586-026-10429-3
- https://www.nature.com/articles/s41586-026-10838-4
- https://www.nature.com/articles/s41586-026-10837-5